 "Alembic Pharma gains as Panelav unit receives EIR from USFDA")
Alembic Pharmaceuticals has moved higher by 6% to Rs 700 on the BSE after the drug maker receives Establishment Inspection Report (EIR) from US drug regulator for its formulation facility located at Panelav, Gujarat.
“The company’s Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016,” Alembic Pharmaceuticals said in a regulatory filing.
Formulations which account for 65% of the total business today has manufacturing facility at three different places; namely Vadodara & Panelav at Gujarat in the west & Baddi at Himachal Pradesh in the north. The facility at Panelav enjoys certifications from international regulatory authorities like MHRA (UK), MCC (South Africa), according to company’s website.
At 11:29 am, the stock was up 3% at Rs 678 on the BSE, against 0.14% decline in the S&P BSE Sensex. A combined 189,633 shares changed hands on the BSE and NSE so far.
“The company’s Formulation Facility located at Panelav has received Establishment Inspection Report (EIR) from US Food & Drug Administration (FDA) for the inspection carried out by them in March, 2016,” Alembic Pharmaceuticals said in a regulatory filing.
Formulations which account for 65% of the total business today has manufacturing facility at three different places; namely Vadodara & Panelav at Gujarat in the west & Baddi at Himachal Pradesh in the north. The facility at Panelav enjoys certifications from international regulatory authorities like MHRA (UK), MCC (South Africa), according to company’s website.
At 11:29 am, the stock was up 3% at Rs 678 on the BSE, against 0.14% decline in the S&P BSE Sensex. A combined 189,633 shares changed hands on the BSE and NSE so far.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%